Patents Examined by Kara D Johnson
  • Patent number: 11116871
    Abstract: Compositions comprising perforated, unseparated amnion/chorion; perforated, separated amnion; and perforated, separated chorion derived from the placenta and methods of preparing and using those compositions are provided. Perforation of placental tissue before or during processing may allow for one or more benefits such as more efficient removal of blood remnants, retention of wound healing and tissue regeneration components, better handling characteristics, or improved healing capacity. The present invention also includes methods of healing a wound of the skin, eye, nerve, tendon, or dura comprising applying the perforated compositions of the invention to the wound.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: September 14, 2021
    Assignee: STIMLABS LLC
    Inventors: John Daniel, Sarah Griffiths, Richard Berg
  • Patent number: 11096967
    Abstract: The present invention relates to a composition and a method for inducing CD4+ T cells to differentiate into regulatory T cells and proliferate through an induced T cell co-stimulator ligand (ICOSL) or an ICOSL-overexpressing mesenchymal stem cell and for preventing or treating regulatory T cell-mediated diseases. The induced T cell co-stimulator ligand (ICOSL) or ICOSL-overexpressing mesenchymal stem cell according to the present invention effectively suppresses the proliferation of PBMCs, induces the expression of an ICOS in regulatory T cells, thereby inducing the differentiation and proliferation of the regulatory T cells through a PI3K-Akt mechanism, and thus can effectively prevent, treat, or enhance regulatory T cell-mediated diseases.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: August 24, 2021
    Assignee: SCM LIFESCIENCE CO., LTD.
    Inventors: Sun Uk Song, Tac Ghee Yi, Hyun Joo Lee
  • Patent number: 11090333
    Abstract: Embodiments of the disclosure concern methods and compositions related to cancer therapy using myeloid derived suppressor cells (MDSC) as a solo therapy or an adjunct therapy. The MDSCs are prepared by exposing bone marrow cells or blood cells to one or more compositions that induce their differentiation to MDSCs and also to TGF-?1, and in specific embodiments the exposure to TGF-?1 results in the MDSCs having anti-tumor activity and/or immune stimulatory activity.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: August 17, 2021
    Assignee: Baylor College of Medicine
    Inventors: Andrew Sikora, Padmini Jayaraman, Falguni Parikh, Robin Parihar
  • Patent number: 11085019
    Abstract: Disclosed herein are precursory regulatory cytotrophoblast cells produced in vitro and compositions thereof. Also disclosed herein are methods of treating a disorder or condition by utilizing the cells disclosed herein.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: August 10, 2021
    Assignee: ACCELERATED BIOSCIENCES CORP.
    Inventors: Jau-Nan Lee, Yuta Lee, Tony Tung-Yin Lee
  • Patent number: 11045578
    Abstract: The invention provides a three dimensional (3D), porous, biodegradable and biocompatible tissue engineering scaffold, wherein at least 25% w/w of the scaffold is particulate egg shell membrane (ESM) distributed substantially uniformly therein and the scaffold is essentially dry. Methods for preparing the same by freeze-drying and cryogelation and the use thereof in methods of tissue engineering and to promote the healing of wounds are also provided.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: June 29, 2021
    Assignee: BIOVOTEC AS
    Inventors: Enda Kenny, Ralf Schmidt, Henri-Pierre Suso, Matthias Schnabelrauch, Annika Wartenberg
  • Patent number: 11027044
    Abstract: An object of the present invention is to provide a method for producing a sheet-like cell structure having excellent strength and shape-maintaining performance, and a sheet-like cell structure having excellent strength and shape-maintaining performance. According to the present invention, there is provided a method for producing a sheet-like cell structure, including: a step of adding a biocompatible macromolecular block, a cell, and a liquid medium onto a culture support body having a plurality of recessed portions on a culture surface, and immersing the biocompatible macromolecular block and the cell in uppermost portions of the recessed portions; and a step of culturing the cell to obtain a sheet-like cell structure.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: June 8, 2021
    Assignee: FUJIFILM Corporation
    Inventor: Kentaro Nakamura
  • Patent number: 11016083
    Abstract: The present invention provides a method for screening for platelet production promoters, the method including a step for selecting a candidate substance that significantly increases expression of TUBB1 as a platelet production promoter.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: May 25, 2021
    Assignees: Kyoto University, Megakaryon Corporation
    Inventors: Koji Eto, Hideya Seo, Akira Ota, Yukitaka Ito, Yasuko Hazama
  • Patent number: 11007231
    Abstract: The main characteristic of method is that before the onset of menopause in women at age 30-45 years, part of the cortical and medulla layers of one or both ovaries is surgically resected and cryopreserved (frozen), and in perimenopause beginning, these tissues are autotransplanted subcutaneously in a form of suspension or small ovarian pieces prepared from thawed tissues fragments of their own ovaries. This “return” is repeatedly periodically each 4-6 months for 10-15 years. That helps to obtain normal level of ovarian antiage factors in blood till age 60-65 years, thus slowing aging.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: May 18, 2021
    Inventor: Nikolai Rukhliada
  • Patent number: 11001811
    Abstract: Provided herein are artificial lung organoids. The artificial lung organoids may include an epithelial cell layer comprising mammalian lung epithelial cells, a stromal cell layer comprising mammalian lung fibroblast cells and an endothelial cell layer comprising mammalian endothelial cells. The artificial lung organoids may optionally include a porous membrane between said epithelial cell layer and said stromal cell layer and/or between said stromal cell layer and said endothelial lung cell layer.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: May 11, 2021
    Assignee: Wake Forest University Health Sciences
    Inventors: Sean V. Murphy, Anthony Atala
  • Patent number: 10993965
    Abstract: The present disclosure is drawn to compositions and methods of making and using lyophilized platelet lysates. Specifically, a method of preparing a composition suitable for therapeutic use or as a culture medium can comprise steps of concentrating platelets from a platelet source to form a platelet rich portion of the platelet source, and lysing the platelets in the platelet rich portion to form a plurality of lysates. An additional step includes lyophilizing the lysates to form lyophilized platelet lysates in a composition with released concentrations of available growth factors, cytokines, and chemokines. In one example, at 30%, by platelet count, of platelets from a platelet source can be lysed using this process.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: May 4, 2021
    Assignee: Jadi Cell LLC
    Inventor: Amit Patel
  • Patent number: 10980837
    Abstract: The present disclosure is drawn to compositions and methods of making and using lyophilized platelet lysates. Specifically, a method of preparing a composition suitable for therapeutic use or as a culture medium can comprise steps of concentrating platelets from a platelet source to form a platelet rich portion of the platelet source, and lysing the platelets in the platelet rich portion to form a plurality of lysates. An additional step includes lyophilizing the lysates to form lyophilized platelet lysates in a composition with released concentrations of available growth factors, cytokines, and chemokines. In one example, at 30%, by platelet count, of platelets from a platelet source can be lysed using this process.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: April 20, 2021
    Assignee: Jadi Ceil LLC
    Inventor: Amit Patel
  • Patent number: 10975350
    Abstract: A cell culture substrate comprising a substrate having a coating of a plurality of amine functionalized nanoparticles is disclosed. In one embodiment, the amine functionalized nanoparticle is a polymer of an acrylamide monomer, a cross-linker and an amine monomer. There is also provided a method of making the cell culture substrate either by drying the amine functionalized nanoparticles when spread onto the said substrate or by covalent linkages of the substrate with thiol terminated nanoparticles. In addition, there is provided a method of culturing stem cells on the cell culture substrate having a coating of a plurality of the amine functionalized nanoparticles thereon.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: April 13, 2021
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Jackie Y. Ying, Nandanan Erathodiyil, Karthikeyan Narayanan, Andrew C. A. Wan
  • Patent number: 10973225
    Abstract: The invention discloses a vitrification freezing treatment device for cells. The vitrification freezing treatment device for cells includes a straw device, a pre-freezing device, a freezing unit, a driving device, a control unit and a carrying table used for carrying cell carriers, wherein the straw device is connected with the driving device in a driven mode, the driving device is in signal connection with the control unit, the straw device comprises straws used for obtaining cells in the cell carriers, the control unit is used for controlling the driving device to drive the straw device to obtain cells and to transfer the cells to the freezing unit, and the pre-freezing device is used for pre-freezing the straws when the straw device transfers the obtained cells to the freezing unit.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: April 13, 2021
    Assignee: Shenzhen Vitavitro BiotechCo., Ltd
    Inventors: Xiaozhen Lin, Gabor Vajta
  • Patent number: 10968285
    Abstract: The present invention discloses a matrix comprising a modified polysaccharide consisting of repeating disaccharide units whereby in at least 11% of the disaccharide units one primary alcohol group is oxidized into a carboxylic acid group.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: April 6, 2021
    Assignee: Albert-Ludwigs Universität Freiburg
    Inventors: V. Prasad Shastri, Aurelien Forget
  • Patent number: 10954490
    Abstract: Described are cell culture solutions and systems for epithelial stem cell and organoid cultures, formation of epithelial constructs and uses of the same in transplantation.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: March 23, 2021
    Assignees: The Brigham and Women's Hospital, Inc., Massachusetts Institute of Technology
    Inventors: Jeffrey Michael Karp, Xiaolei Yin, Marc David Succi, Robert Samuel Langer
  • Patent number: 10952975
    Abstract: Resistance of randomly dispersed and oxygen-starved lung tumor cells to chemo- and radiotherapy constitutes the vast majority recurrences and death from lung cancer. We use sickle cells derived from humans with sickle cell anemia to target oxygen-deprived tumor cells that persist and multiply after conventional treatment. Transfused sickle cells selectively occluded tumor microvessels and shut down blood flow to these oxygen-deprived pockets leading to tumor cell death and complete shrinkage of aggressive lung tumors. Combining the sickle cells with a vascular disrupting agents and radiation injure and narrow tumor blood vessels, amplified the scale of sickle cell-induced blood vessel closure and tumor cell killing. The strength of the tumor killing produced by this combination exceeded that of either agent alone or combined with conventional anti-angiogenics, chemotherapy or radiation.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: March 23, 2021
    Inventor: David S Terman
  • Patent number: 10946043
    Abstract: Methods of inducing a polarization of macrophages. The method includes obtaining a blood fraction, fractionating the blood fraction to produce a blood fraction, and contacting the blood fraction with a source of macrophages. A blood fraction including platelet-poor plasma polarizes the source of macrophages into M1 macrophages. A blood faction including a protein solution polarizes the source of macrophages into M2 macrophages.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: March 16, 2021
    Assignee: Biomet Biologics, LLC
    Inventors: Jennifer E. Woodell-May, Joel C. Higgins, William King
  • Patent number: 10947509
    Abstract: The present invention provides methods for the sequential and temporally-regulated administration of pancreatic transcription factors to induce non-pancreatic cells to transdifferentiate and mature along the pancreatic ?-cell lineage. The present invention also provides methods for identifying, isolating and enriching transdifferentiation predisposed cells and methods for treating a degenerative pancreatic disorder such as diabetes.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: March 16, 2021
    Assignees: ORGENESIS LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventor: Sarah Ferber
  • Patent number: 10940184
    Abstract: The present application relates to use of transglutaminases to treat various tissue matrix products. The methods can include application of a transglutaminase to a partially denatured collagen-containing tissue matrix and implantation of the tissue matrix. The transglutaminase can facilitate adhesion with another collagen-containing tissue matrix, tissue surrounding the tissue matrix after implantation, or both.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: March 9, 2021
    Assignee: LifeCell Corporation
    Inventors: Eric Stec, Ming F. Pomerleau, Rick T. Owens, Richard Seeman
  • Patent number: 10918673
    Abstract: Provided herein is technology relating to immunoisolation of cells and tissues, including, but not exclusively, to compositions, methods, and kits for encapsulating cells and/or tissues within an immunoisolating device to protect the cells/or tissues from host immune rejection.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: February 16, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventor: Ariella Shikanov